SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
170.15
+6.26 (+3.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close163.89
Open164.19
Bid166.25 x 800
Ask176.84 x 800
Day's Range164.15 - 170.45
52 Week Range72.05 - 172.70
Volume614,798
Avg. Volume932,761
Market Cap13.27B
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
    Benzinga

    The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) * AbbVie Inc (NYSE: ABBV) * ADC Therapeutics SA (NYSE: ADCT) * Affimed NV (NASDAQ: AFMD) * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Akero Therapeutics Inc (NASDAQ: AKRO) (announced positive results for mid-stage study of NASH drug) * Amgen, Inc. (NASDAQ: AMGN) (reacted to a favorable court ruling on its Enbrel patent litigation) * Aptinyx Inc (NASDAQ: APTX) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Crispr Therapeutics AG (NASDAQ: CRSP) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Legend Biotech Corp (NASDAQ: LEGN) * Liminal BioSciences Inc (NASDAQ: LMNL) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) * Natera Inc (NASDAQ: NTRA) * Opko Health Inc. (NASDAQ: OPK) * Pacira Biosciences Inc (NASDAQ: PCRX) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Twist Bioscience Corp (NASDAQ: TWST) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Generation Bio Co (NASDAQ: GBIO) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Iterum Therapeutics PLC (NASDAQ: ITRM) * Repare Therapeutics Inc (NASDAQ: RPTX)Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS) said it has finalized its previously disclosed agreement with the U.S. Attorney's Office for the Southern District of New York, the New York State attorney general and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis in the U.S.The litigation pertains to Novartis allegedly spending millions of dollars on incentive programs to doctors who steered patients toward drugs from its cardiovascular division in exchange for illegal kickbacks.As part of this settlement, Novartis said it will pay $678 million and has agreed to new corporate integrity obligations with the Office of Inspector General of the Department of Health & Human Services that will change how the company delivers peer-to-peer programs in the U.S. The company said it had fully provisioned for this settlement in July 2019.The stock was down 0.66% at $87.27 premarket Thursday.Merck Closes Licensing Transaction With Ridgeback To Advance COVID-19 Treatment Candidate Merck & Co., Inc. (NYSE: MRK) announced the closing of its collaboration and licensing agreement with antiviral biotech Ridgeback Biotherapeutics following the FTC granting early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.The companies noted that all closing requirements have been completed for the previously announced partnership transaction to advance the development of EIDD-2801, an investigational, orally available antiviral agent in early clinical development for the treatment of patients with COVID-19.The stock was trading 0.87% higher at $78.80 at the time of publication Thursday.See also: The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week BeiGene Announces Acceptance Of Chinese Regulatory Application For Tislelizumab Label Expansion Beigene Ltd (NASDAQ: BGNE) said the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for its anti-PD-1 antibody tislelizumab in patients with previously treated unresectable hepatocellular carcinoma, the most common form of liver cancer.Unity Biotech Announces Second-Half Clinical Catalysts Offering a clinical trial update, Unity Biotechnology Inc (NASDAQ: UBX) said it expects to release top-line 12-week results from Phase 2 study of UBX0101 in osteoarthritis in the third quarter. The company also said it plans to initiate a first-in-human study of UBX1325 in age-related eye diseases in the second half of 2020.Sarepta In-Licenses Pre-Treatment Candidate For Its Gene Therapies For $407.5M Sarepta Therapeutics Inc (NASDAQ: SRPT) and Hansa Biopharma announced an agreement under which Sarepta is granted an exclusive worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy.Sarepta will pay Hansa $10 million upfront and up to $397.5 million in development, regulatory and sales milestone payments. The agreement calls for Sarepta assuming responsibility for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals, and also promoting imlifidase as a pre-treatment to Sarepta's gene therapies following potential approval.Offerings Zomedica Pharmaceuticals Corp (NYSE: ZOM) said it has priced its previously announced public offering of 187.5 million shares of its common stock, together with short-term warrants, to purchase up to 187.5 million common shares at a combined public offering price of 16 cents per share and accompanying warrant.Each common share is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of 16 cents per common share, the company said. Zomedica expects to raise gross proceeds of $30 million from the offering.The stock was down 33.26% premarket at 15 cents.Neoleukin Therapeutics Inc (NASDAQ: NLTX) said it intends to offer up to 5 million shares of its common stock and, in lieu of common stock, to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. All of the securities are being offered by the company.The stock slipped 6% to $15.99 in after-hours trading.BioLife Solutions Inc (NASDAQ: BLFS) said it intends to offer shares of its common stock for sale in an underwritten public offering. The company said it expects to use the gross proceeds for general corporate purposes.The stock was down 7.61% premarket at $14.82. Related Link: Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'See more from Benzinga * Global Blood Analyst Projects More Than 60% Upside On Receding Sickle Cell Drug Concerns * Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Sarepta Addressing Gene Therapy Issue With Two Acquisitions
    GuruFocus.com

    Sarepta Addressing Gene Therapy Issue With Two Acquisitions

    Biotech’s shares trading near all-time high of $172. It is also working on Covid-19 treatment Continue reading...

  • Sarepta Inks Agreement With Codiak to Develop Gene Therapies
    Zacks

    Sarepta Inks Agreement With Codiak to Develop Gene Therapies

    Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.

  • Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting
    SmarterAnalyst

    Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting

    Sarepta Therapeutics (SRPT) has announced that it has teamed up with Codiak BioSciences to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases.According to Sarepta, the engineered exosome approach offers the potential to effectively deliver genetic therapeutics without triggering the adaptive immune response.The two-year agreement includes up to five neuromuscular targets. Codiak is eligible to receive up to $72.5 million in upfront and near-term license payments plus research funding, as well as milestone payments and tiered royalties on future sales. Sarepta is granted an option to any of the candidates developed as part of the research alliance.Exosomes are natural nanoparticles that serve as the body’s intercellular communication system, facilitating the transfer of a wide variety molecular payloads between cells. Through its proprietary engEx Platform, Codiak can design exosomes with precisely engineered properties, incorporate various types of biologically active molecules and direct them to specific cell types.“Codiak’s engEx technology could potentially address some of the limitations of current treatment approaches and offers broad utility across Sarepta’s therapeutic modalities” commented Sarepta CEO Doug Ingram. “Codiak’s exosomes are engineered for precise tissue targeting and offer a non-viral delivery approach with non-immunogenic potential, thus opening up avenues for more efficient delivery and potential re-dosing,” he added.If Sarepta elects to exercise its option on a target, Codiak will be responsible for research and preclinical development through IND preparation, and Sarepta will take charge of clinical development and commercial activities.Shares in Sarepta have spiked 33% year-to-date, and analysts have a bullish Strong Buy consensus on the stock’s outlook. That’s with a $197 average analyst price target (14% upside potential). (See Sarepta stock analysis on TipRanks)However, Oppenheimer’s Hartaj Singh is taking a more cautious approach. He recently reiterated his Hold rating on the stock without a price target, writing “While Sarepta continues to enhance its gene therapy manufacturing scale-up across its platform of programs, we await clarity on several key aspects for the DMD (Duchenne Muscular Dystrophy) program (SRP-9001).”For Singh, success for the name hinges on several key SRP-9001 steps: scale-up (GMP material by July), study 301’s initiation (2H20), study 102’s readout in 1Q21 and what size/scope of 301 data will support a registrational filing.Related News: Sanofi, Translate Bio Ramp Up Billion-Dollar mRNA Vaccine Collaboration Evoke Pharma Pops 86% On FDA Approval Of Gimoti Nasal Spray Apyx Spikes 45% In Pre-Market On Nod To Sell Helium Products In New Countries More recent articles from Smarter Analyst: * The Rise of E-Commerce and Cloud Services Positions Amazon (AMZN) for the Win * Facebook Faces More Ad Boycotts, But This Analyst Expects Minimal Impact * 3 "Strong Buy" Penny Stocks With Explosive Upside Ahead * Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst

  • Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks

    Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?

    Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?

    Is (SRPT) Outperforming Other Medical Stocks This Year?

  • Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdle
    Motley Fool

    Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdle

    Early safety data for the potential one-shot cure for the lethal muscle wasting disorder looks encouraging.

  • Sarepta's Gene Therapy Promising in Muscular Dystrophy Study
    Zacks

    Sarepta's Gene Therapy Promising in Muscular Dystrophy Study

    Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.

  • Sarepta Therapeutics' Shares March Higher, Can It Continue?
    Zacks

    Sarepta Therapeutics' Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Sarepta Therapeutics.

  • Sarepta Beats Its Own Gene Therapy Expectations — And Shares Surge
    Investor's Business Daily

    Sarepta Beats Its Own Gene Therapy Expectations — And Shares Surge

    Three children with muscular dystrophy continued to show improvements a year after receiving Sarepta's experimental gene therapy, the biotech said Monday. In response, SRPT stock jumped.

  • Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?
    Zacks

    Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?

    Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is Sarepta Therapeutics Inc (SRPT) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Sarepta Therapeutics Inc (SRPT) Going to Burn These Hedge Funds?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

  • Thomson Reuters StreetEvents

    Edited Transcript of SRPT earnings conference call or presentation 6-May-20 8:30pm GMT

    Q1 2020 Sarepta Therapeutics Inc Earnings Call

  • Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year?

    Is (SRPT) Outperforming Other Medical Stocks This Year?

  • Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data
    Zacks

    Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data

    Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.

  • Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy
    Zacks

    Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

    Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

  • Why Sarepta Has A Leg Up On Pfizer With A Rival Gene Therapy: Analysts
    Investor's Business Daily

    Why Sarepta Has A Leg Up On Pfizer With A Rival Gene Therapy: Analysts

    Sarepta Therapeutics still has a leg up on Dow Jones pharma company Pfizer, analysts said Friday after the latter posted updated results of a gene therapy test and SRPT stock popped.

  • Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics
    Motley Fool

    Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics

    Pfizer (NYSE: PFE) released fairly promising data from its trial for the gene therapy PF-06939926 in boys with Duchenne muscular dystrophy. In a phase 1b clinical trial, treatment with PF-06939926 resulted in expression of dystrophin, the protein that's missing in patients with Duchenne muscular dystrophy. The three patients given the lower dose had an average of 24% of normal expression of dystrophin in muscle biopsies taken 12 months after treatment with PF-06939926.

  • When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit?
    Simply Wall St.

    When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit?

    Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT): Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company...

  • Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy
    Kiplinger

    Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy

    It has been noted ad nauseam that the stock market doesn't appear to reflect the worst economic slowdown since the Great Depression. The Dow Jones Industrial Average is down "only" 17% for the year to date, while the S&P; 500 is off "just" 11%.If that bothers you, don't even look at the Nasdaq Composite. This tech-heavy index of Nasdaq-listed stocks is actually positive, albeit barely, for 2020.Whether share prices adequately discount the potential damage caused by the global lockdown and a prolonged recession is a discussion for another time. Besides, investors usually find it more profitable not to fight the tape.With that in mind, we went searching for the Nasdaq stocks that analysts say have the best prospects for outperformance going forward.We screened the Nasdaq Composite for stocks followed by a minimum of 10 analysts. We further whittled the list down to stocks with an average broker recommendation of Buy or better. S&P; Capital IQ surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell. Any score of 2.0 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call. Lastly, we dug into research, analysts' estimates and other data on the top-scoring names.The process gave us a host of stocks, from small biotechnology plays to some of the biggest, best-known companies in the world. Have a look at 15 of the best Nasdaq stocks, according to the pros. SEE ALSO: 50 Top Stock Picks That Billionaires Love

  • Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
    Zacks

    Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

    Sarepta (SRPT) Q1 revenues increase year over year.

  • Sarepta Therapeutics (SRPT) Q1 2020 Earnings Call Transcript
    Motley Fool

    Sarepta Therapeutics (SRPT) Q1 2020 Earnings Call Transcript

    SRPT earnings call for the period ending March 31, 2020.

  • Sarepta Reports Earnings Miss; But Key SRP-9001 Data Still On Track
    SmarterAnalyst

    Sarepta Reports Earnings Miss; But Key SRP-9001 Data Still On Track

    Sarepta Therapeutics (SRPT) has reported weaker-than-expected earning results for the first quarter. Specifically, Q1 Non-GAAP EPS of -$1.04 missed Street expectations by $1.75 while GAAP EPS of -$0.23 also fell short by $0.67.Although total product revenue of $100.4M climbed 15.4% year-over-year, it nonetheless missed the Street consensus by $17.78M. Sarepta ended the quarter with a cash position of $2.2 bn.Encouragingly, CEO Doug Ingram revealed that “our placebo-controlled gene therapy clinical trial, study 102, for SRP-9001 is on track to read out in the first quarter of 2021 as anticipated.” SRP-9001 micro-dystrophin is a potential treatment for Duchenne Muscular Dystrophy (DMD), a genetic condition that leads to progressive loss of muscle strength.“Additionally, our process development, assay and manufacturing work for SRP-9001 is progressing and we continue to expect GMP [good manufacturing practice] material to be ready in July” he said.Plus clinical data from the company’s second gene therapy program – SRP-9003 in LGMD2E – is expected in 2Q20 as previously guided.With these comments in mind, Mizuho Securities analyst Difei Yang reiterated her buy rating and $183 price target. “Covid-19 is likely to have some impacts on product sales in FY20 and we believe 2020 revenue guidance is at risk” she warned- particularly for Exondys51.But despite the expected short-term revenue impact from Covid-19, ultimately the analyst “continue[s] to see significant value in Sarepta’s gene therapy pipeline, including SRP-9001.” She sees Covid-19 as having minimal long-term impact to SRPT and therefore maintains her bullish stance.Moreover, Yang believes that the read out for study 102 in 1Q21 could represent an important catalyst for the shares. So far the stock is down just over 5% on a year-to-date basis, and is falling 4% in Thursday’s pre-market trading.Overall, analysts shares Yang’s take on Sarepta, with 12 recent buy ratings vs just 1 hold rating. This gives the stock a firm Strong Buy consensus. The average analyst price target of $199 indicates significant upside potential of 63% from current levels. (See SRPT stock analysis on TipRanks).Related News: Japan Plans To Approve Gilead’s Remdesivir Today- Report AstraZeneca Wins FDA Approval For Diabetes Drug to Treat Heart Failure Global Blood Therapeutics Reports Q1 Beat, Impressive Oxbryta Sales More recent articles from Smarter Analyst: * Taiwan Semi Has Not Received Any Assurance On US License For Huawei Tech Sale * Buffett’s Berkshire Shaves Off 84% Of Its Goldman Sachs Stake * Apple is Said to Snap Up Startup NextVR For Virtual Reality Content; Top Analyst Sees Buying Opportunity * Carl Icahn Initiates Position in Delek US Holdings, Boosts Occidental Petroleum

  • Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 89.96% and 0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?